TriangleDISEASE & TREATMENT SETTING
KEYTRUDA QLEX: Breast cancer (neoadjuvant) after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.18 Triple-Negative Breast Cancer KEYTRUDA QLEX is indicated for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Broader topic: Breast Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- neoadjuvant
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- after surgery
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for KEYTRUDA QLEX (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.18 Triple-Negative Breast Cancer KEYTRUDA QLEX is indicated for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice